MENU
+Compare
KNSA
Stock ticker: NASDAQ
AS OF
Aug 5, 04:59 PM (EDT)
Price
$33.06
Change
+$0.11 (+0.33%)
Capitalization
2.44B

KNSA stock forecast, quote, news & analysis

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases... Show more

KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for KNSA with price predictions
Aug 04, 2025

KNSA in upward trend: price rose above 50-day moving average on July 29, 2025

KNSA moved above its 50-day moving average on July 29, 2025 date and that indicates a change from a downward trend to an upward trend. In of 37 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 29, 2025. You may want to consider a long position or call options on KNSA as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for KNSA just turned positive on July 29, 2025. Looking at past instances where KNSA's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for KNSA crossed bullishly above the 50-day moving average on July 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KNSA advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KNSA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

KNSA broke above its upper Bollinger Band on August 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KNSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.933) is normal, around the industry mean (17.871). KNSA's P/E Ratio (659.000) is considerably higher than the industry average of (58.473). KNSA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.530). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (4.638) is also within normal values, averaging (278.698).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Sarepta Therapeutics (NASDAQ:SRPT), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.34B. The market cap for tickers in the group ranges from 58 to 213.02B. NONOF holds the highest valuation in this group at 213.02B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 20%, and the average quarterly price growth was 13%. JWCTF experienced the highest price growth at 158%, while VYNE experienced the biggest fall at -75%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was 68% and the average quarterly volume growth was 71%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 59
SMR Rating: 100
Profit Risk Rating: 95
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
2 Church Street
Phone
+44 8081896257
Employees
297
Web
https://www.kiniksa.com